PIIE analysis finds Trump's 2025 fentanyl tariffs failed to curb flows from China

Tariffs are the familiar part of this story. The unfamiliar part is the claim they were supposed to solve a fentanyl crisis. A new PIIE analysis says that link never really held — not in the data, not in the policy design, and not in the courts. The basic point is blunt: Trump’s 2025 fentanyl tariffs on China moved around a lot, but the overdose trend was already moving before the policy showed up. Then the Supreme Court took the tool away. ### What actually happened? Trump imposed the first China fentanyl tariff on February 1, 2025, using the International Emergency Economic Powers Act, or IEEPA. The White House framed it as a response to China’s role in precursor chemicals, money laundering, and supply-chain support for synthetic opioids reaching the United States. The initial extra duty was 10%. (piie.com) ### Why did the rate keep changing? Because this was never a stable trade regime. On March 3, 2025, Trump doubled the China fentanyl tariff from 10% to 20%, saying Beijing had not taken adequate steps. Then on November 4, 2025, the White House cut it back to 10%, saying China had committed to tighter controls on certain chemicals and exports. So the policy lurched from 10 to 20 and back to 10 in nine months. (whitehouse.gov) ### Did those tariffs reduce fentanyl harm? PIIE says there is no clean reason to think so. Noland’s point is that fentanyl deaths had already started falling before the second Trump administration took office, which makes it hard to credit the 2025 tariffs for the decline. He also argues that drug epidemics do not move in a tidy, tariff-like way — they rise and recede for messy reasons tied to users, supply networks, substitutes, enforcement, and survival itself. (whitehouse.gov) ### Why is that such a hard thing to prove? Because tariffs hit legal imports, while fentanyl markets route through illicit networks, precursor chemicals, re-shippers, and transnational criminal groups. Even the White House orders described a system built on concealment and indirect flows, not neat container-by-container trade. That makes a tariff a pretty blunt instrument — more like raising the drawbridge on one gate when the smuggling paths run through tunnels, side doors, and intermediaries. (piie.com) ### So what killed the policy? The Supreme Court did. In *Learning Resources v. Trump*, decided February 20, 2026, the Court held that IEEPA does not authorize the president to impose tariffs. The case covered both the broader reciprocal tariffs and the drug-trafficking tariffs, including the China fentanyl duties. That means the policy did not just weaken politically — it lost its legal foundation. (whitehouse.gov) ### Why does PIIE care about the legal angle? Because the paper is really about limits on presidential trade power. The easy story is that tariffs are pure leverage — Washington threatens, Beijing yields. But this episode shows domestic institutions matter too. Courts, statutory language, and the choice of legal authority shaped the policy as much as the bilateral standoff did. In other words, the constraint was not only China. (supremecourt.gov) It was also U.S. law. ### Does this mean fentanyl enforcement failed? Not exactly. Border agencies are still seizing fentanyl and precursor chemicals, and CBP continues to frame the issue as a live enforcement fight. But that is a different claim from saying a tariff on Chinese goods solved the problem. One is about interdiction and policing. The other is about whether import duties can reliably bend an illicit opioid market. (piie.com) PIIE’s answer is basically no. ### Bottom line? This is less a story about one tariff schedule than about the limits of using trade law as a weapon against a drug crisis. Trump’s 2025 fentanyl tariffs were politically dramatic, economically noisy, and legally fragile. The overdose decline cannot be cleanly pinned on them — and by February 2026, the Court had already erased them anyway. (piie.com) (cbp.gov)